Anthropic filed an S-1 with the SEC for a Nasdaq IPO. It plans to list under the ticker 'ANT'. The company targets a $100bn raise and a $2trn valuation. It aims to compress decades of scientific progress into years. It will use AI to accelerate drug discovery, disease detection and personalised therapy. It introduced Powerful AI to match or exceed top human experts. Powerful AI will also control lab equipment and robotic systems. Anthropic already launched Claude Science for drug discovery workflows. It is pursuing its own drug development for neglected diseases. It partners with Novo Nordisk, Bristol Myers Squibb, AbbVie and Sanofi. It warned its models may behave in unintended or harmful ways. Pharma AI partnership values rose 120% year-on-year between 2024 and 2025.
What changed
Anthropic had not filed for an IPO and had not publicly detailed Powerful AI.
What it unlocks
Listing on Nasdaq under ticker 'ANT' and accelerating drug discovery with AI.
- $100bn IPO raise target
- $2trn potential valuation
- 120% YoY pharma AI partnership value growth 2024-2025